Danielle Brill
Stock Analyst at Raymond James
(1.23)
# 3,523
Out of 4,884 analysts
75
Total ratings
32.81%
Success rate
-10.46%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $14.28 | +264.15% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $21.19 | +206.75% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $14.90 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $57.17 | +38.18% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $8.62 | +108.82% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $129.40 | +19.78% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $16.81 | +114.16% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $32.12 | +24.53% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $18.20 | +724.40% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $133.19 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $9.08 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $457.03 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $545.11 | +10.99% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $21.24 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $33.37 | +49.84% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $35.35 | +44.27% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $53.17 | -19.13% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.41 | +1,130.62% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $49.15 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.25 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $14.28
Upside: +264.15%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $21.19
Upside: +206.75%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.90
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $57.17
Upside: +38.18%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.62
Upside: +108.82%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $129.40
Upside: +19.78%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $16.81
Upside: +114.16%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $32.12
Upside: +24.53%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $18.20
Upside: +724.40%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $133.19
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $9.08
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $457.03
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $545.11
Upside: +10.99%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $21.24
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $33.37
Upside: +49.84%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $35.35
Upside: +44.27%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $53.17
Upside: -19.13%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.41
Upside: +1,130.62%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $49.15
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.25
Upside: -